Who is helping whom? Manuscript support and transfer of value. Ann Neurol 2015;77:353-5.
Wechsler, R, RA Hauser, and J French. 2015. “Who Is Helping Whom? Manuscript Support and Transfer of Value. Ann Neurol 2015;77:353-5.”. Ann Neurol.
Search
Search results
1500 results found
Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol 2015:38:163-9.
Simon, DK, C Wu, BC Tilley, AM Wills, MJ Aminoff, J Bainbridge, RA Hauser, et al. 2015. “Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol 2015:38:163-9.”. Clin Neuropharmacol.
A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. Int J Neurosci 2018;128:619-626.
Lew, MF, A Breashear, K Dashtipour, S Isaacson, RA Hauser, P Maisonobe, D Snyder, and W Ondo. 2018. “A 500 U/2 mL Dilution of AbobotulinumtoxinA Vs. Placebo: Randomized Study in Cervical Dystonia. Int J Neurosci 2018;128:619-626.”. Int J Neurosci.
Hauser RA, Truong D. Tardive dyskinesia: Out of the shadows. J Neurol Sci 2018;389:1-3.
“Hauser RA, Truong D. Tardive Dyskinesia: Out of the Shadows. J Neurol Sci 2018;389:1-3.”. 2018. J Neurol Sci.
Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord 2016;31:1366-72.
Hauser, RA, CW Olanow, B Dzyngel, T Bilbault, H Shill, S Isaacson, J Dubow, and A Agro. 2016. “Sublingual Apomorphine (APL-130277) for the Acute Conversion of OFF to ON in Parkinson’s Disease. Mov Disord 2016;31:1366-72.”. Mov Disord.
Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology 2017;89:2495-2502.
Schobel, SA, G Palermo, P Auinger, JD Long, S Ma, OS Khwaja, D Trundell, 2CARE Huntington Study Group Investigators, and . 2017. “Motor, Cognitive, and Functional Declines Contribute to a Single Progressive Factor in Early HD. Neurology 2017;89:2495-2502.”. Neurology.
Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease. Eur J Neurol 2014;21:736-43.
Hauser, RA, AH Shapira, P Barone, Y Mizuno, O Rascol, M Busse, C Debieuvre, M Fraessdorf, and W Poewe. 2014. “Long-Term Safety and Sustained Efficacy of Extended-Release Pramipexole in Early and Advanced Parkinson’s Disease. Eur J Neurol 2014;21:736-43.”. Eur J Neurol.
Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using 123I-Ioflupane Injection (DaTscan) Imaging. J Nucl Med 2014;55:1288-1296.
Seibyl, JP, A Kupsch, J Booij, DG Grosset, DC Costa, RA Hauser, J Darcourt, N Bajaj, Z Walker, and . 2014. “Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects With Parkinsonian Syndrome or Dementia Using 123I-Ioflupane Injection (DaTscan) Imaging. J Nucl Med 2014;55:1288-1296.”. J Nucl Med.
Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. Eur J Neurol 2013;20:50-6.
Schapira, AH, P Barone, RA Hauser, Y Mizuno, O Rascol, M Busse, C Debieuvre, M Fraessdorf, and W Poewe. 2013. “Patient-Reported Convenience of Once-Daily versus Three-Times-Daily Dosing During Long-Term Studies of Pramipexole in Early and Advanced Parkinson’s Disease. Eur J Neurol 2013;20:50-6.”. Eur J Neurol.
AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies. J Neural Transm 2013;120:299-307.
Hauser, RA, D Truong, J Hubble, C Coleman, JL Beffy, S Chang, and P Picaut. 2013. “AbobotulinumtoxinA (Dysport) Dosing in Cervical Dystonia: An Exploratory Analysis of Two Large Open-Label Extension Studies. J Neural Transm 2013;120:299-307.”. J Neural Transm.